Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (secukinumab)

• Main Authors: Bruna Lavinas Sayed Picciani (Author), Arkadiusz Dziedzic (Author), Juliana Tristão Werneck (Author), Marcello Alves Marinho (Author), Thaylla Núñez Amin Dick (Author), Nara Regina Quintanilha (Author), Eliane Pedra Dias (Author)
• Format: Book
• Published: BMC, 2021-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Secukinumab is a human monoclonal antibody immunoglobulin that neutralises interleukin (IL)-17A, and as such, is effective in the treatment of psoriasis. However, as IL-17A is essential in protection against fungal infections, patients treated with this drug may develop candidias...